Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Ethical reflections: how to solve a problem like… ghostwriti...

Claire Nicholson continues to ethically reflect in her monthly series and this time approaches the topic of ghostwriting. The topic of ghostwriting in the medical / scientific sphere is not new – it has been written about widely in both the medical literature and in...

Articles

Rare is different: patients and caregivers are key drivers o...

In part three of the ‘Rare is different’ series, Katie Mihelich shares some powerful experiences of rare disease patients and caregivers, and explains why it’s important for pharma marketers to acknowledge their elevated level of empowerment. Fifty percent of rare disease patients are children and 80 percent of rare disease patients are diagnosed during...

Articles

Comparative effectiveness evidence: Comparing apples and ora...

Pharmaceutical companies face increasing demands for effectiveness evidence, and thus escalating costs. Here Jeanni van Loon describes a mean to generate evidence without the need for additional trials. Development plans typically identify comparators that will meet regulatory needs and go some way to meeting the needs of other...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.